A double-blind, placebo controlled cross-over study of the effects of the CB2 compound of GW842166 [GW 842166X] in patients with osteoarthritis.
Phase of Trial: Phase II
Latest Information Update: 13 Jul 2017
At a glance
- Drugs GW 842166X (Primary)
- Indications Musculoskeletal pain; Osteoarthritis
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 27 Oct 2008 Actual end date changed from Nov 2007 to Oct 2007 as reported by Clinicaltrials.gov.
- 12 Oct 2008 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
- 08 May 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.